Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Jan 16, 2021 12:45pm
207 Views
Post# 32313456

RE:RE:Looks like Brokers Didn't buy overalotment

RE:RE:Looks like Brokers Didn't buy overalotmentA conspiracy theory here could be that the banks striped all the warrants off the shares and only sold shares to their retail and small clients, so the pitch would be the stock is around $3 and you can buy for $2.59 (there's a cost split in the prospectus). And the warrants are all going to one investor who said they would invest at $3.19 for 15% of company over next 3 years and would exercise a bit each year to fund programs.  Total conspiracy that can easily be debunked if you did get a unit of share + warrant in your offering. 

realitycheck4u wrote:

It was substantially over subscribed.  I got 1/10th of what I was looking for so that additional allotment will occur  

 

archeo753 wrote:

 

 

Theratechnologies to list additional shares Jan. 19

 

2021-01-15 20:37 ET - Prospectus Approved

 

The Toronto Stock Exchange reports that Theratechnologies Inc. will list additional shares at the open on Jan. 19, 2021. As stated in its prospectus supplement dated Jan. 13, 2021, the company will issue 14,546,000 units at $2.75 (U.S.) per unit in a public offering, with each unit consisting of one share and one-half warrant.

According to the TSX, the units will separate upon the closing of the offering. Each whole warrant will entitle the holder to acquire one share of the company at $3.18 (U.S.) for 36 months following the closing of the offering. The warrants will not be listed and posted for trading on the TSX.

© 2021 Canjex Publishing Ltd. All rights reserved.





<< Previous
Bullboard Posts
Next >>